This one is for adults with primary advanced or recurrent endometrial cancer.

"This new approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868. Results reported last year in the New England Journal of Medicineshowed a 70% lower risk of disease progression when patients were treated with pembrolizumab and chemotherapy."
#Immunology #Immunotherapy #CheckpointInhibitor
https://www.cancerresearch.org/blog/june-2024/keytruda-receives-40th-fda-approval?utm_source=Social&utm_medium=LinkedIn&utm_campaign=CRI&utm_id=CRI